Alzheimer's disease is characterized by histological changes in the brain, including extracellular amyloid plaques that are composed of the amyloid-β peptide (Aβ), and intracellular neurofibrillary ...

With recent trial failures dashing hopes for treating Alzheimer’s with γ-secretase inhibitors (see ARF news story and ARF news story), scientists are redoubling efforts to develop compounds that tweak ...

Can γ-secretase modulators stage a comeback? Scientists led by Irene Gerlach at F. Hoffmann-La Roche, Basel, Switzerland, are banking on it. At this year’s CTAD meeting, held October 24-27 in Boston, ...

New research has uncovered the early assembly of gamma-secretase, a protein complex linked to numerous cellular processes including the development of Alzheimer's disease. In a first step, two dimeric ...

A research team led by Wim Annaert (VIB-KU Leuven) uncovered the early assembly of gamma-secretase, a protein complex linked to numerous cellular processes including the development of Alzheimer's ...

A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. Background: Aberrant Notch signaling is ...

Using artificial intelligence, researchers show how γ-secretase recognizes substrates - an important advance for fundamental and translational research. The γ-secretase enzyme is capable of cleaving ...

Preliminary results of a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (DOC) with or without estramustine (E) as first-line treatment for castration-resistant ...

With each new amyloid-targeting treatment for Alzheimer's disease that has been developed, there has been a corresponding concern. For example, antibodies targeting amyloid-beta peptide produce ...

Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial ...